Rapport Therapeutics Inc (RAPP)

$14.83 -0.59 (-3.83%)
Market Cap 562.80M
Revenue (ttm) 0.00
Net Income (ttm) -78.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 122,900
Avg Vol 191,920
Day's Range N/A - N/A
Shares Out 36.50M
Stochastic %K 22%
Beta N/A
Analysts Strong Sell
Price Target $35.00

Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including periphe...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 321 8020
Address:
1325 Boylston Street, Suite 401, Boston, United States
UCF_16
UCF_16 Jul. 24 at 11:36 PM
$FIX $RAPP $SCHL $WLGS Lets go $WLGS - to the moon 🌗 🎆🚀🔥
0 · Reply
Whiskey1679
Whiskey1679 Jul. 24 at 11:35 PM
Whiskeya Picks out tomorrow approx. 6:20 am PDT! Trending: $SCHL $FIX $RAPP $WLGS $BMIX
0 · Reply
Quantumup
Quantumup Jul. 18 at 12:46 PM
H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine, for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG NBIX ( LBPH - HLBBF HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures, there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed vormatrigine's potential in FOS—we make that statement despite being "bulls" on the vormatrigine story. We believe the efficacy that relutrigine demonstrated in the EMBOLD study was potentially paradigm-shifting in its ability to offer seizure freedom to patients. H.C. Wainwright went on to say:
0 · Reply
Quantumup
Quantumup Jul. 16 at 10:02 AM
Citizens reiterated $RAPP Market Outperform-$28 after a KOL call reinforced its confidence in the pot'l for positive RAP-219 Phase 2 results in focal epilepsy. $PRAX $XENE $BHVN $NBIX TAK UCBJY Citizens said in its note: "We recently hosted Dr. Vikram Rao, a neurologist from UCSF and epilepsy KOL, for a discussion on the upcoming Phase 2 proof-of-concept results for RAP-219 in focal epilepsy. Dr. Rao is optimistic about the potential for RAP-219 in focal epilepsy due to its validated yet differentiated mechanism of action, compelling preclinical results, and innovative Phase 2 trial design. RAPP remains one of our two high-conviction calls into the Phase 2 results in September."
0 · Reply
oneyedjacks
oneyedjacks Jul. 10 at 8:04 PM
$RAPP Garbage
0 · Reply
JarvisFlow
JarvisFlow Jul. 8 at 2:15 PM
JMP Securities has updated their rating for Rapport Therapeutics ( $RAPP ) to Market Outperform with a price target of 28.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 1 at 10:58 AM
$RAPP Rapport Therapeutics files $400M mixed securities shelf
0 · Reply
bilocelhi
bilocelhi Jun. 4 at 2:04 PM
$AGEN and $RAPP my top 2 bios
0 · Reply
QuiverQuant
QuiverQuant Jun. 2 at 8:07 PM
Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline Read more on $RAPP: https://www.quiverquant.com/news/Rapport+Therapeutics+Hosts+Inaugural+Investor+and+Analyst+Day+to+Update+on+RAP-219+and+Clinical+Pipeline
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 2 at 7:53 PM
$ZONE -22%[64%] $NIVF 4%[-12%] $KIDZ 3%[38%] $GPUS 3%[-12%] $RAPP 3%[15%] most notable movement into the final minutes of trading.
0 · Reply
Latest News on RAPP
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

Jun 2, 2025, 2:45 PM EDT - 2 months ago

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 7:00 AM EDT - 2 months ago

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 21, 2025, 7:00 AM EDT - 2 months ago

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

May 8, 2025, 7:00 AM EDT - 3 months ago

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Mise à disposition du rapport financier annuel 2024

Apr 30, 2025, 11:45 AM EDT - 3 months ago

Mise à disposition du rapport financier annuel 2024

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Apr 22, 2025, 7:00 AM EDT - 3 months ago

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

Apr 18, 2025, 7:46 AM EDT - 3 months ago

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024

Mar 27, 2025, 7:00 AM EDT - 4 months ago

Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024

Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE

Mar 21, 2025, 2:26 PM EDT - 4 months ago

Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Mar 21, 2025, 7:00 AM EDT - 4 months ago

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 13, 2025, 12:14 PM EDT - 4 months ago

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 13, 2025, 3:00 AM EDT - 5 months ago

Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 11, 2025, 7:00 AM EDT - 5 months ago

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Mar 3, 2025, 7:00 AM EST - 5 months ago

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Jan 9, 2025, 9:12 AM EST - 7 months ago

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Jan 9, 2025, 7:00 AM EST - 7 months ago

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Dec 6, 2024, 12:01 PM EST - 8 months ago

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Nov 14, 2024, 7:00 AM EST - 9 months ago

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Nov 4, 2024, 7:00 AM EST - 9 months ago

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Oct 18, 2024, 10:51 AM EDT - 10 months ago

This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

COFS NEON PCT SELF

Rapport semestriel Pilier 3 - 30 juin 2024

Sep 17, 2024, 2:35 AM EDT - 11 months ago

Rapport semestriel Pilier 3 - 30 juin 2024

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Sep 5, 2024, 7:00 AM EDT - 11 months ago

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

Jun 7, 2024, 11:48 AM EDT - 1 year ago

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

JNJ

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

Jun 6, 2024, 7:57 PM EDT - 1 year ago

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

JNJ

Rapport Therapeutics Announces Pricing of Initial Public Offering

Jun 6, 2024, 6:54 PM EDT - 1 year ago

Rapport Therapeutics Announces Pricing of Initial Public Offering

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

Jun 3, 2024, 1:14 PM EDT - 1 year ago

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

JNJ

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

May 22, 2024, 4:17 PM EDT - 1 year ago

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

UCF_16
UCF_16 Jul. 24 at 11:36 PM
$FIX $RAPP $SCHL $WLGS Lets go $WLGS - to the moon 🌗 🎆🚀🔥
0 · Reply
Whiskey1679
Whiskey1679 Jul. 24 at 11:35 PM
Whiskeya Picks out tomorrow approx. 6:20 am PDT! Trending: $SCHL $FIX $RAPP $WLGS $BMIX
0 · Reply
Quantumup
Quantumup Jul. 18 at 12:46 PM
H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine, for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG NBIX ( LBPH - HLBBF HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures, there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed vormatrigine's potential in FOS—we make that statement despite being "bulls" on the vormatrigine story. We believe the efficacy that relutrigine demonstrated in the EMBOLD study was potentially paradigm-shifting in its ability to offer seizure freedom to patients. H.C. Wainwright went on to say:
0 · Reply
Quantumup
Quantumup Jul. 16 at 10:02 AM
Citizens reiterated $RAPP Market Outperform-$28 after a KOL call reinforced its confidence in the pot'l for positive RAP-219 Phase 2 results in focal epilepsy. $PRAX $XENE $BHVN $NBIX TAK UCBJY Citizens said in its note: "We recently hosted Dr. Vikram Rao, a neurologist from UCSF and epilepsy KOL, for a discussion on the upcoming Phase 2 proof-of-concept results for RAP-219 in focal epilepsy. Dr. Rao is optimistic about the potential for RAP-219 in focal epilepsy due to its validated yet differentiated mechanism of action, compelling preclinical results, and innovative Phase 2 trial design. RAPP remains one of our two high-conviction calls into the Phase 2 results in September."
0 · Reply
oneyedjacks
oneyedjacks Jul. 10 at 8:04 PM
$RAPP Garbage
0 · Reply
JarvisFlow
JarvisFlow Jul. 8 at 2:15 PM
JMP Securities has updated their rating for Rapport Therapeutics ( $RAPP ) to Market Outperform with a price target of 28.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 1 at 10:58 AM
$RAPP Rapport Therapeutics files $400M mixed securities shelf
0 · Reply
bilocelhi
bilocelhi Jun. 4 at 2:04 PM
$AGEN and $RAPP my top 2 bios
0 · Reply
QuiverQuant
QuiverQuant Jun. 2 at 8:07 PM
Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline Read more on $RAPP: https://www.quiverquant.com/news/Rapport+Therapeutics+Hosts+Inaugural+Investor+and+Analyst+Day+to+Update+on+RAP-219+and+Clinical+Pipeline
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 2 at 7:53 PM
$ZONE -22%[64%] $NIVF 4%[-12%] $KIDZ 3%[38%] $GPUS 3%[-12%] $RAPP 3%[15%] most notable movement into the final minutes of trading.
0 · Reply
lecorb
lecorb May. 29 at 12:29 PM
$REVB $NTLA $RAPP Crashed
0 · Reply
mikedumbledar
mikedumbledar May. 29 at 11:59 AM
$RAPP why down 25%? i dont see any news
0 · Reply
JarvisFlow
JarvisFlow Apr. 8 at 4:45 PM
JMP Securities has adjusted their stance on Rapport Therapeutics ( $RAPP ), setting the rating to Market Outperform with a target price of 28.
0 · Reply
_www_larval_com_
_www_larval_com_ Apr. 7 at 7:58 PM
$LHSW 6%[12%] $ARTV 4%[40%] $BJDX -3%[112%] $RAPP -3%[7%] most notable movement into the final minutes of trading.
0 · Reply
jParkz
jParkz Apr. 5 at 9:01 PM
News out $RAPP (RAPP) Investment Analysis https://marketwirenews.com/news-releases/-rapp-investment-analysis-5446057280009633.html $RAPP
0 · Reply
Josephylor
Josephylor Apr. 4 at 7:46 PM
$RAPP In today's market downturn, savvy investors recognize that opportunities often arise when stocks are undervalued. Nuvve stands out as a compelling investment during these times.​ Competitive Edge: ✅ Advanced vehicle-to-grid (V2G) technology ✅ Bidirectional Charging: Unlike many competitors, Nuvve enables EVs to return power to the grid, enhancing grid efficiency ✅ AI-Powered Energy Management: Utilizes artificial intelligence to optimize energy flow and stabilize the grid ✅ Revenue Generation for EV Owners: Allows EV owners and fleet operators to earn by selling excess energy back to the grid
0 · Reply
Cutlass
Cutlass Mar. 27 at 7:31 PM
$RAPP Stay away - no pipeline, will need to do an offering too - 📉📋📣👀
0 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 11:14 AM
$RAPP Rapport Therapeutics sees cash runway through 2026 The Company ended the fourth quarter with $305.3 million in cash, cash equivalents and short-term investments, compared to $320.7 million as of September 30, 2024. The decrease was primarily due to cash outflows on operating activities in the fourth quarter of 2024. The Company expects that cash, cash equivalents, and short-term investments as of December 31, 2024 will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 11 at 11:13 AM
$RAPP Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year "With continued execution in the fourth quarter, Rapport is well positioned to deliver on multiple meaningful development milestones. The RAP-219 Phase 2a trial in patients with refractory focal epilepsy continues to advance with strong momentum; patient enrollment and dosing are progressing as planned, and the trial remains on track to deliver topline results in the third quarter of 2025. Based on data from 100 healthy subjects dosed, we continue to have confidence in RAP-219's potential as a transformational medicine. The recently released PET and MAD-2 trial results demonstrated neuroanatomical specificity and favorable tolerability, further reinforcing our belief in its differentiated precision profile," said Abraham Ceesay, CEO. "We are committed to the pipeline-within-a-product strategy for RAP-219 and anticipate initiating a Phase 2a trial in bipolar mania in the third quarter of this year while continuing planning for our Phase 2a trial in diabetic peripheral neuropathic pain."
0 · Reply
_www_larval_com_
_www_larval_com_ Mar. 6 at 8:52 PM
$RAPP 4%[-23%] $YOSH -4%[14%] $SCNX 4%[15%] most notable movement into the final minutes of trading.
0 · Reply
FurrrMom
FurrrMom Mar. 5 at 12:37 AM
Giving credit where credit is due, I wouldn't have taken 37% profit on $RAPP if these guys hadn't called it when they did. No idea how they get ahead of these runners like they do. Had to be at least half-a-dozen today alone!
0 · Reply
IntraTrades
IntraTrades Mar. 4 at 9:47 PM
$RAPP 50.68% $ATLN 40.12% $HOTH 36.11% $CLEU 35.98% $CTM 34.51%
0 · Reply